Since the clinical trial with birabresib (MK-8628) did not report relatively high toxicity, I-CBP112 may be similarly or better tolerated, particularly when the toxicity profiles of BET inhibitors, which include thrombocytopenia, fatigue, and diarrhea, emerge as class effects [17]. Here, DNER is linked to Thrombocytopenia.